Strengthening melanoma prevention and early detection among people with type 2 diabetes

Abstract

Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. Br J Dermatol 2021; 185:745-55.3 Amagai M, Tsunoda K, Zillikens D et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile.